U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H26N4O4S
Molecular Weight 454.542
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EMPA

SMILES

CCN(CC1=CN=CC=C1)C(=O)CN(C2=CN=C(OC)C=C2)S(=O)(=O)C3=CC=CC=C3C

InChI

InChIKey=KJPHTXTWFHVJIG-UHFFFAOYSA-N
InChI=1S/C23H26N4O4S/c1-4-26(16-19-9-7-13-24-14-19)23(28)17-27(20-11-12-22(31-3)25-15-20)32(29,30)21-10-6-5-8-18(21)2/h5-15H,4,16-17H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C23H26N4O4S
Molecular Weight 454.542
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulphonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA) is a high-affinity, reversible and selective orexin type 2 (OX2) receptor antagonist. The in vivo activity of EMPA was assessed by reversal of orexin-B-induced hyperlocomotion during the resting phase in mice and the reduction of spontaneous locomotor activity (LMA) during the active phase in rats.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
1.1 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct

PubMed

Sample Use Guides

In Vivo Use Guide
Male NMRI mice: Mice were injected i.p. with EMPA (1, 3, 10, 30, 100, 300 mg·kg−1, n= 8 mice per dose). Male Wistar rats: one hour after the dark period onset, rats were injected i.p. with EMPA (3, 10, 30 mg·kg−1, n= 8 rats per dose) and immediately placed into the activity monitoring chambers.
Route of Administration: Intraperitoneal
In Vitro Use Guide
The distribution and abundance of in vitro binding sites of [3H]EMPA (1 nmol·L−1), measured by quantitative autoradiography and image analysis, was investigated in coronal rat brain sections. A high density of specific binding was observed in many brain regions including the limbic cortices, hippocampus, striatum and hypothalamic nuclei. Non-specific binding (NSB), determined in the presence of 10 µmol·L−1 Cp-5, a selective OX2 receptor antagonist.
Substance Class Chemical
Record UNII
VT87V86D7W
Record Status Validated (UNII)
Record Version